Esorubicin (deoxydoxorubicin) has low grade activity in malignant melanoma - Results of an Eastern Cooperative Oncology Group study (EST 2685)

Howard Hochster, Myla Hunt, Michael Green, David Parkinson, Thomas Smith

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

In this phase II trial, twenty patients with advanced, measurable melanoma from ECOG institutions were treated with esorubicin 30 mg/m2 iv every three weeks. Doses were escalated or reduced based on nadir counts. The dose limiting toxicity was leukopenia with no significant thrombocytopenia or anemia. Other toxicities were mild. One patient had skin necrosis with extravasation. Two patients with soft tissue disease had partial remissions and were treated with 9 and 17 courses. One patient was stable for 8 courses. No cardiac toxicity was seen in three patients receiving more than 150 mg/m2. The response rate was 10% (90% CI = 2 to 30%). Low level activity was seen, but it is unlikely that this drug has sufficient activity to warrant further development in melanoma.

Original languageEnglish (US)
Pages (from-to)329-332
Number of pages4
JournalInvestigational New Drugs
Volume8
Issue number3
DOIs
StatePublished - Aug 1990

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Keywords

  • clinical
  • deoxydoxorubicin
  • esorubicin
  • melanoma

Fingerprint Dive into the research topics of 'Esorubicin (deoxydoxorubicin) has low grade activity in malignant melanoma - Results of an Eastern Cooperative Oncology Group study (EST 2685)'. Together they form a unique fingerprint.

Cite this